Disease Progression in Myotonic Dystrophy Research on myotonic dystrophy type 1 (DM1) has led to the recognition of a new paradigm for muscle disease. The mutation in DM1, an expanded CTG repeat in the 3'untranslated region of DMPK, is unstable in somatic cells. The expansion continues to increase in size in muscle cells during postnatal life, reaching lengths of several thousand repeats. The mechanisms underlying this unusual genetic behavior, and the relationships among increasing repeat length and onset or progression of DM1, have not been determined. Deleterious effects of the mutation are mediated by the mutant RNA, which contains an expanded CUG repeat (CUGexp). Recent findings in transgenic mouse models have identified several cellular pathways that are affected by CUGexp RNA, such as, MBNL1 sequestration and upregulation of CUGBP1 or NKX2.5. However, which of these mechanisms are primarily responsible for muscle degeneration in human DM1 is in question. This multifaceted project brings together a large collaborative team to study the mechanisms for repeat instability and the relationships among CTG repeat length, biochemical changes, and muscle impairment in individuals with DM1. Our goal is to focus therapeutic effort on the targets that are most pertinent to DM1 progression. Studies of pathogenesis will be tightly coordinated with prospective longitudinal follow up in a cohort of individuals with DM1. The goal of this analysis is to define rates of DM1 progression and determine which outcomes are most sensitive for monitoring disease progression and suitable as endpoints in clinical trials.
Aim 1 employs a new method for cell free cloning of CTG repeats to study the effects of cell division, genomic position, transcription, and oxidative damage on stability of highly expanded CTG repeats in human cells.
Aim 2 examines the relationships among repeat length, biochemical changes, and weakness in the same muscle.
Aim 3 compares loss of muscle bulk and strength over time with functional impairments that are characterstic of DM1. Overall, this project will supply critical information that is needed to move forward with therapeutic development in DM1.
|Johnson, Nicholas E; Ekstrom, Anne-Berit; Campbell, Craig et al. (2016) Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy. Dev Med Child Neurol 58:698-705|
|Slean, Meghan M; Panigrahi, Gagan B; Castel, Arturo LÃ³pez et al. (2016) Absence of MutSÎ² leads to the formation of slipped-DNA for CTG/CAG contractions at primate replication forks. DNA Repair (Amst) 42:107-18|
|Fitzgerald, Bryan P; Conn, Kelly M; Smith, Joanne et al. (2016) Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy. J Neurol 263:2528-2537|
|Heatwole, Chad; Bode, Rita; Johnson, Nicholas E et al. (2016) Myotonic dystrophy health index: Correlations with clinical tests and patient function. Muscle Nerve 53:183-90|
|Gloss, David; Moxley 3rd, Richard T; Ashwal, Stephen et al. (2016) Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86:465-72|
|Heatwole, Chad; Johnson, Nicholas; Bode, Rita et al. (2015) Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2). Neurology 85:2136-46|
|Yadava, Ramesh S; Foff, Erin P; Yu, Qing et al. (2015) TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy. Hum Mol Genet 24:2035-48|
|Pandey, Sanjay K; Wheeler, Thurman M; Justice, Samantha L et al. (2015) Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J Pharmacol Exp Ther 355:329-40|
|Wojtkowiak-Szlachcic, Agnieszka; Taylor, Katarzyna; Stepniak-Konieczna, Ewa et al. (2015) Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Nucleic Acids Res 43:3318-31|
|Smith, Amanda E; McMullen, Kara; Jensen, Mark P et al. (2014) Symptom burden in persons with myotonic and facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil 93:387-95|
Showing the most recent 10 out of 74 publications